Showing 8101-8110 of 8647 results for "".
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”https://modernod.com/news/for-world-sight-day-horizon-and-prevent-blindness-are-calling-on-the-thyroid-eye-disease-ted-community-to-put-vision-first/2476979/In support of World Sight Day, Horizon Therapeutics and Prevent Blindness launched a campaign that brings together the voices of the thyroid eye disease (TED) community to educate the public on how TED can damage vision and encourage people who are living with TED to put their vision first by sha
- Mynosys Secures $25 Million Investment; Names Rob Thornhill as CEOhttps://modernod.com/news/mynosys-secures-25-million-investment-names-rob-thornhill-as-ceo/2476976/Mynosys Cellular Devices, manufacturer of the Zepto cataract surgery device, announced it finalized a $25 million financing round, led by Decheng Capital, and named veteran ophthalmology industry executive Rob Thornhill as Chief Executive Officer. This financing provides capital to fuel U.
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel
- EyeGate Pharma Completes Randomization in Pivotal Studyhttps://modernod.com/news/eyegate-pharma-completes-randomization-in-pivotal-study/2476965/EyeGate Pharmaceuticals announced that it has completed randomization for its corneal wound repair pivotal study using the Ocular Bandage Gel eye drop.
- Genentech/Roche Complete Enrollment in YOSEMITE and RHINE Phase 3 Studies of Faricimab in DMEhttps://modernod.com/news/genentech-roche-complete-enrollment-in-yosemite-and-rhine-phase-3-studies-of-faricimab-in-dme/2476957/Genentech and Roche announced they have completed patient enrollment in the phase 3 YOSEMITE (
- Zeiss and Senorics Establish Partnership Focus on Joint Development of Sensor Technologyhttps://modernod.com/news/zeiss-and-senorics-establish-partnership-focus-on-joint-development-of-sensor-technology/2476952/Zeiss announced that it has invested in Dresden, Germany-based Senorics. The partnership aims to further the joint development of small and cost-effective sensors for industrial use in quality assurance and in process monitoring, e.g. on production lines for foodstuffs, agricultural products, pla
- Report: Chocolate May Not Help Your Visionhttps://modernod.com/news/report-chocolate-may-not-help-your-vision/2476938/In disappointing news for chocolate lovers, researchers have found that contrary to an earlier report, eating dark chocolate will not improve your vision, according to a Reuters report. The earlier report suggested that certain aspects of
- Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturinghttps://modernod.com/news/ocugen-and-cansinobio-enter-strategic-partnership-for-gene-therapy-co-development-and-manufacturing/2476929/Ocugen has entered into a strategic partnership with CanSino Biologics on Ocugen’s gene therapy pipeline product candidates for inherited retinal diseases, which are currently in development with Schepens Eye Research Institute of Massachusetts Eye and Ear, an affiliate of Harvard Medical Schoo
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f